Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSMD.L Regulatory News (SMD)

  • There is currently no data for SMD

Director/PDMR Shareholding

11 Jan 2022 07:00

RNS Number : 9963X
Spectral MD Holdings, Ltd.
11 January 2022
 

 

11 January 2022

Spectral MD Holdings, Ltd

("Spectral MD" or the "Company" or the Group") 

 

Director/PDMR Shareholding

 

LONDON, U.K AND DALLAS, TX, U.S. - Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company that develops proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, has been notified that on 10 January 2022, Gerald Beaney, a non-executive director, has purchased 13,333 shares of common stock of US$0.001 ("Common Stock") each in the capital of the Company ("Shares") at a price of 37.5 pence per Share for a total consideration of £5,000.

 

As a result, Gerald Beaney's beneficial interest in the Company is 30,283 shares of Common Stock , representing 0.02% of the total issued share capital.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

 

Gerald Beaney

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-executive director

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Spectral MD Holdings, Ltd

b)

 

LEI

 

 

213800VXW1FVGWTCKL44

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Shares of common stock of US$0.001 each

Identification code

USU8457V1099

 

b)

 

Nature of the transaction

 

 

Purchase of Shares

c)

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

37.5p

13,333

 

 

 

d)

 

Aggregated information

 

Volume

Price

 

 

13,333

£4,999.88

e)

 

Date of the transaction

 

 

10 January 2022

f)

 

Place of the transaction

 

 

London Stock Exchange

 

 

For further information, please contact:

 

 

 

Spectral MD Holdings, Ltd.

https://investors.spectralmd.com/

Wensheng Fan, Chief Executive Officer

Nils Windler, Chief Financial Officer

via Walbrook PR

 

 

SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)

+44 (0) 20 3470 0470

Stuart Gledhill / Caroline Rowe (Corporate Finance)

Vadim Alexandre / Rob Rees (Sales and Corporate Broking)

 

Stifel Nicolaus Europe Limited (Joint Broker)

+44 (0) 20 7710 7600

Charles Hoare / Ben Maddison / Will Palmer-Brown

 

 

 

Walbrook PR Ltd (Media & Investor Relations)

+44 (0)20 7933 8780 or spectralMD@walbrookpr.com

Paul McManus / Sam Allen

Louis Ashe-Jepson

 

+44 (0)79 8054 1893/ +44 (0)75 0255 8258

+44 (0) 7747 515393

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHDGGDBXDBDGDG
12
Date   Source Headline
10th May 20227:00 amRNSPublication of Annual Financial Report
13th Apr 20227:00 amRNSAppointment: V.P of Marketing
21st Mar 20227:00 amRNSFinal Results
9th Mar 20227:00 amRNSNotice of Full Year Results
4th Feb 20227:00 amRNSGrant of share options and cash bonus
1st Feb 20227:00 amRNSTrading Update and Notice of Results
11th Jan 20227:00 amRNSDirector/PDMR Shareholding
23rd Dec 20213:13 pmRNSShare Dealing and Exercise of Options
21st Dec 20217:00 amRNSGrant of share options and Management update
1st Dec 20217:00 amRNSAppointment of CFO
18th Nov 20217:00 amRNSEnrolment Completed for DFU Training Study
16th Nov 20217:00 amRNSClinical results presented at US Burn Conference
20th Oct 20217:00 amRNSAppointment of Joint Broker
11th Oct 20212:00 pmRNSGrant of share options
13th Sep 20217:00 amRNSHalf-year Report
7th Sep 20217:00 amRNSNotice of Results
9th Aug 20217:00 amRNSKick-off event to launch clinical study
15th Jul 20217:00 amRNSHolding(s) in Company
24th Jun 20217:00 amRNSContract Award from US Department of Defense
22nd Jun 20217:00 amRNSAdmission to trading on AIM; First Day of Dealings
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.